OVID
Ovid Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$386.63M
P/E Ratio
—
EPS
$-0.23
Beta
-0.03
52W High
$2.72
52W Low
$0.25
50-Day MA
$1.85
200-Day MA
$1.36
Dividend Yield
—
Profit Margin
-240.10%
Forward P/E
1.79
PEG Ratio
0.00
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $7.25M |
| Gross Profit (TTM) | $7.25M |
| EBITDA | $-42.17M |
| Operating Margin | -1712.00% |
| Return on Equity | -17.50% |
| Return on Assets | -21.80% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $1.00 |
| Price-to-Book | 2.55 |
| Price-to-Sales (TTM) | 53.31 |
| EV/Revenue | 38.17 |
| EV/EBITDA | -0.69 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 845.00% |
| Shares Outstanding | $151.03M |
| Float | $101.22M |
| % Insiders | 8.49% |
| % Institutions | 41.00% |
Analyst Ratings
Consensus ($4.79 target)
11
BuyData last updated: 4/8/2026